Alnylam Pharmaceuticals Inc. (ALNY)

67.61
0.20 0.29
NASDAQ : Health Technology
Prev Close 67.81
Open 66.75
Day Low/High 65.89 / 67.78
52 Wk Low/High 60.27 / 124.22
Volume 374.97K
Avg Volume 967.70K
Exchange NASDAQ
Shares Outstanding 106.54M
Market Cap 7.23B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Alnylam Announces Alignment On Value-Based Agreements With Leading Health Insurers And Launches Comprehensive Patient Support Services For ONPATTRO™ (patisiran)

Alnylam Announces Alignment On Value-Based Agreements With Leading Health Insurers And Launches Comprehensive Patient Support Services For ONPATTRO™ (patisiran)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has agreed on the structure and key terms of value-based agreements (VBA) with leading health insurers for ONPATTRO™ (patisiran) lipid complex...

ONPATTRO™ (patisiran) Packaging And Product Vial (Photo: Business Wire)

ONPATTRO™ (patisiran) Packaging And Product Vial (Photo: Business Wire)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) approved ONPATTRO™ (patisiran) lipid complex injection, a first-of-its-kind RNA interference...

Alnylam Announces That The United Kingdom's MHRA Grants Early Access To Patisiran

Alnylam Announces That The United Kingdom's MHRA Grants Early Access To Patisiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted patisiran, an investigational RNAi therapeutic in development for the...

Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2018 and highlighted recent progress in advancing its pipeline.

Alnylam To Webcast Conference Call Discussing Second Quarter 2018 Financial Results

Alnylam To Webcast Conference Call Discussing Second Quarter 2018 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2018 on Thursday, August 2, 2018, before the U.

Alnylam Receives Positive CHMP Opinion For ONPATTRO™ (patisiran) For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults With Stage 1 Or Stage 2 Polyneuropathy

Alnylam Receives Positive CHMP Opinion For ONPATTRO™ (patisiran) For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults With Stage 1 Or Stage 2 Polyneuropathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a Positive Opinion recommending marketing authorization of patisiran for the...

Alnylam Presents New Analyses Of Clinical Results From APOLLO Phase 3 Study Of Patisiran At 2018 Peripheral Nerve Society Annual Meeting

Alnylam Presents New Analyses Of Clinical Results From APOLLO Phase 3 Study Of Patisiran At 2018 Peripheral Nerve Society Annual Meeting

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the Company presented new analyses from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary...

Alnylam Announces Publication Of APOLLO Phase 3 Clinical Study Results For Investigational RNAi Therapeutic Patisiran In The New England Journal Of Medicine

Alnylam Announces Publication Of APOLLO Phase 3 Clinical Study Results For Investigational RNAi Therapeutic Patisiran In The New England Journal Of Medicine

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the pivotal study results from the APOLLO Phase 3 trial of patisiran were published online today in The New England Journal of Medicine (NEJM).

Alnylam To Host Fifth Annual "RNAi Roundtable" Webcast Series

Alnylam To Host Fifth Annual "RNAi Roundtable" Webcast Series

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 5 th annual series of "RNAi Roundtable" webcasts this summer.

Alnylam Expands Senior Leadership Team With Two Key Appointments

Alnylam Expands Senior Leadership Team With Two Key Appointments

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointments of two accomplished biotech executives, Masako Nakamura as Senior Vice President, Head of Asia, and Jing L.

Alnylam To Report New Clinical Results For Patisiran At The 4th Congress Of The European Academy Of Neurology

Alnylam To Report New Clinical Results For Patisiran At The 4th Congress Of The European Academy Of Neurology

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR)...

Over 700 Alnylam Employees Volunteer At The Company's 4th Annual "Helping Hands" Community Service Day

Over 700 Alnylam Employees Volunteer At The Company's 4th Annual "Helping Hands" Community Service Day

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today kicked off its fourth annual company-wide "Helping Hands" Community Service Day benefiting 23 organizations, including 16 organizations in the Greater Boston area...

Alnylam Reports Updated Positive Results From Phase 1/2 Study Of Lumasiran In Patients With Primary Hyperoxaluria Type 1 (PH1)

Alnylam Reports Updated Positive Results From Phase 1/2 Study Of Lumasiran In Patients With Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase (GO) for the treatment of...

Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For ALN-TTRsc02, A Subcutaneously Delivered Investigational RNAi Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis

Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For ALN-TTRsc02, A Subcutaneously Delivered Investigational RNAi Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALN-TTRsc02, an investigational RNAi therapeutic for the...

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Bernstein 34 th Annual Strategic Decisions Conference on Friday, June 1, 2018...

Alnylam Appoints Colleen Reitan To The Board Of Directors

Alnylam Appoints Colleen Reitan To The Board Of Directors

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylam's Board of Directors, effective June 1, 2018.

Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery Of RNAi Therapeutics

Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery Of RNAi Therapeutics

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has achieved delivery of novel small interfering RNA (siRNA) conjugates to the central nervous system (CNS) and is planning to advance a...

Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2018 and highlighted recent progress in advancing its pipeline.

Alnylam Achieves Alignment With FDA On Accelerated Development Path For Lumasiran, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Achieves Alignment With FDA On Accelerated Development Path For Lumasiran, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has reached alignment with the U.

Alnylam To Webcast Presentations At Upcoming May Investor Conferences

Alnylam To Webcast Presentations At Upcoming May Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Deutsche Bank 43 rd Annual Healthcare Conference on Tuesday, May 8, 2018...

Alnylam To Webcast Conference Call Discussing First Quarter 2018 Financial Results

Alnylam To Webcast Conference Call Discussing First Quarter 2018 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2018 on Thursday, May 3, 2018, after the U.

Alnylam Reports New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The American Academy Of Neurology 2018 Annual Meeting

Alnylam Reports New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The American Academy Of Neurology 2018 Annual Meeting

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis,...

Alnylam Receives Positive Opinion For Orphan Drug Designation In The European Union For ALN-TTRsc02, A Subcutaneously Delivered Investigational RNAi Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis

Alnylam Receives Positive Opinion For Orphan Drug Designation In The European Union For ALN-TTRsc02, A Subcutaneously Delivered Investigational RNAi Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending...

Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation And Other Pending Litigation

Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation And Other Pending Litigation

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has entered into a settlement agreement with Dicerna Pharmaceuticals resolving trade secret misappropriation claims against Dicerna, and...

Alnylam And Collaborators To Present Clinical Study Results In Acute Hepatic Porphyrias (AHPs) At The 53rd International Liver Congress™ Of The European Association For The Study Of The Liver (EASL)

Alnylam And Collaborators To Present Clinical Study Results In Acute Hepatic Porphyrias (AHPs) At The 53rd International Liver Congress™ Of The European Association For The Study Of The Liver (EASL)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that Alnylam scientists and collaborators will present new results from the Phase 1 and Phase 1/2 open-label extension...

Alnylam Presents New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The 16th International Symposium On Amyloidosis

Alnylam Presents New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The 16th International Symposium On Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company presented new results from the APOLLO Phase 3 study of patisiran, an investigational, RNAi...

Alnylam Receives European Medicines Agency PRIME Designation For Accelerated Assessment Of Lumasiran, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Receives European Medicines Agency PRIME Designation For Accelerated Assessment Of Lumasiran, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for lumasiran...

Alnylam To Webcast Presentation At 17th Annual Needham Healthcare Conference

Alnylam To Webcast Presentation At 17th Annual Needham Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 17 th Annual Needham Healthcare Conference on Wednesday,...

Alnylam To Report New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The 16th International Symposium On Amyloidosis

Alnylam To Report New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The 16th International Symposium On Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational therapeutic for the treatment...

HATTR Amyloidosis Fact Sheet

HATTR Amyloidosis Fact Sheet

For many people living with a rare disease, such as hereditary ATTR (hATTR) amyloidosis, it can take years to be accurately diagnosed.

TheStreet Quant Rating: D (Sell)